Daniel S. Lynch
Daniel S. Lynch is the Executive Chairman and Interim CEO of Surface Oncology, and a strategic advisor at Third Rock Ventures. He brings more than 25 years of experience in biotechnology and pharmaceutical companies, and has active board roles in several companies including Chairman at bluebird bio, Blueprint Medicines, and Rana Therapeutics. Mr. Lynch served as Chief Executive and Chief Financial Officer of ImClone Systems Corp. While at ImClone, he negotiated a major partnership with Bristol-Myers Squibb and helped secure FDA approval of its novel cancer treatment ERBITUX. He has served as executive chair or board member for a number of private biopharmaceutical companies, including Stromedix until its acquisition by Biogen Idec in February 2012, and Avila Therapeutics Inc. until its acquisition by Celgene Corp. in February 2012. Earlier in his career, Mr. Lynch served in various financial positions at Bristol-Myers Squibb over a 15-year tenure. He served on the board of directors and the audit committee of U.S. Oncology Inc. for five years until December 2010 when it was acquired by McKesson. Mr. Lynch received his B.A. in mathematics from Wesleyan University and his MBA from the Darden Graduate School of Business Administration at the University of Virginia.